100% Quality Guarantee
PhD-Level Technical Support
Anti-ROR1 (ziloverta biosimilar) (HDBS0067)
Key Features

Zilovertamab Biosimilar (ROR1) Antibody (HDBS0067)

SKU HDBS0067
Antibody Type Biosimilar Reference Antibody
Applications IHC
Applications FC
Applications Drug Development
Applications Pharmacokinetics
Disease Area Cancer
Protein ROR1
Reactivity Human
Host Species Humanized
Isotype IgG1
€431

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheet

Zilovertamab Biosimilar (ROR1) Antibody (HDBS0067)

The ROR1 Ziloverta Biosimilar (HDBS0067) is a cutting-edge antibody designed for research involving the Receptor tyrosine kinase-like orphan receptor 1 (ROR1). ROR1 is a transmembrane protein that plays a crucial role in cancer progression and metastasis, making it a promising target for cancer therapy.This biosimilar antibody, developed through advanced techniques, is highly specific and reactive with human samples, making it an excellent tool for studying the function of ROR1 in various cell types. Validated for use in Western blot applications, the antibody binds specifically to the ROR1 protein, enabling detailed detection and analysis in research focused on cancer biology and therapeutic development.

ROR1 has been identified as a potential target for cancer treatment due to its overexpression in various cancer types, including leukemia, breast cancer, and lung cancer. By understanding the role of ROR1 in promoting tumor growth and metastasis, researchers can develop targeted therapies that specifically inhibit ROR1 signaling pathways, leading to more effective and personalized cancer treatments.Overall, the Anti-ROR1 Ziloverta Biosimilar (HDBS0067) offers a valuable tool for researchers investigating the role of ROR1 in cancer biology, with the potential to drive advancements in precision medicine and targeted cancer therapies.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose